Rapport Therapeutics (RAPP) announced that the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint, demonstrating a statistically significant reduction in long episodes. In the trial, RAP-219 also showed a statistically significant and clinically meaningful reduction in clinical seizures compared with baseline.
Rapport plans to hold an end-of-Phase 2 meeting with the FDA in the fourth quarter of 2025 and plans to initiate pivotal trials in the third quarter of 2026. The company expects to present additional efficacy analyses and 8-week follow-up results in 2026.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.